DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients
ZURICH-SCHLIEREN, Switzerland, May 16, 2022 /PRNewswire/ -- DiNAQOR announced today the launch of DiNAQOR DiNAMIQS, a biomanufacturing subsidiary, that will accelerate development timelines and reduce costs and risk for genetic medicine companies bringing new treatments to market.
- DiNAQOR DiNAMIQS is based in the company's state-of-the-art, 1,200-square-meter (13,000 square feet) manufacturing facility in Bio-Technopark Schlieren-Zrich, the leading center for biotechnology companies in Central Europe.
- "We look forward to partnering with the world's leading gene therapy companies," said Johannes Holzmeister, M.D., Chairman and CEO of DiNAQOR.
- "There are always challenges in the development process, and DiNAQOR DiNAMIQS is ideally suited to meet and overcome them.
- DiNAQOR DiNAMIQS provides a comprehensive range of manufacturing services, process development, quality control and analytics solutions to support and accelerate gene therapy projects.